Eltrombopag Drugs Market Report 2025

The eltrombopag drugs market size has grown strongly in recent years. It will grow from $2.29 billion in 2024 to $2.49 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be attributed to the rising prevalence of chronic immune thrombocytopenia, increasing use of thrombopoietin receptor agonists in clinical practice, heightened awareness of rare blood disorders among healthcare professionals, growing preference for oral therapies over injectable treatments, and a rise in regulatory approvals across emerging economies.

The eltrombopag drugs market size is expected to see strong growth in the next few years. It will grow to $3.47 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth during the forecast period can be attributed to the rising incidence of hematological disorders worldwide, an expanding geriatric population susceptible to platelet disorders, an increase in clinical trials exploring new indications, growing demand for targeted and personalized therapies, and improved access to healthcare in low- and middle-income countries. Key trends in this period include the same factors: the global rise in hematological disorders, the aging population at risk for platelet disorders, the expansion of clinical trials for additional indications, heightened demand for precision therapies, and enhanced healthcare accessibility in developing regions.

The rising prevalence of thrombocytopenia-related disorders is expected to drive the growth of the eltrombopag drugs market in the coming years. Thrombocytopenia-related disorders are medical conditions marked by abnormally low platelet counts in the blood, which can result in increased bleeding, bruising, and impaired clot formation. The incidence of these disorders is increasing due to the growing prevalence of autoimmune diseases, where the body’s immune system mistakenly destroys healthy platelets. Eltrombopag drugs support the treatment of thrombocytopenia-related disorders by stimulating platelet production through activation of the thrombopoietin receptor, thereby reducing the risk of bleeding complications. For example, according to the US Centers for Disease Control and Prevention (CDC), from 2022 to 2024, the proportion of people with IgM antibodies indicating recent infection rose across all age groups from under 3% to 10% by June 2024, with the largest increase observed in children aged 5 to 9 years, rising from 15% to 40%. Consequently, the growing prevalence of thrombocytopenia-related disorders is propelling the eltrombopag drugs market.

The increasing number of clinical trials is also expected to boost the growth of the eltrombopag drugs market. Clinical trials are research studies conducted in humans to assess the safety, efficacy, and outcomes of medical, surgical, or behavioral interventions. The rising demand for new and effective therapies to address unmet medical needs and emerging health challenges has led to an increase in clinical trials. A larger number of trials supports the development and validation of eltrombopag drugs, facilitating their expanded use in treating blood disorders. For instance, a report by the Association of the British Pharmaceutical Industry (ABPI) in November 2023 noted that the total number of industry clinical trials initiated annually in the UK increased by 4.3%, from 394 trials in 2021 to 411 trials in 2022. Therefore, the growth in clinical trials is driving the eltrombopag drugs market.

Key players in the eltrombopag drugs market are focusing on developing patient-centered drug delivery solutions, such as next-generation oral formulations, to improve therapeutic efficacy and patient compliance. Oral formulations are medications designed to be taken by mouth, including tablets, capsules, or liquid solutions, offering convenient and non-invasive drug delivery. For example, in May 2025, Camber Pharmaceuticals Inc., a US-based company, launched an AB-rated generic version of Promacta eltrombopag to provide cost-effective treatment for thrombocytopenia-related disorders. The product is available in tablet strengths of 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg, as well as an oral suspension delivering 12.5 mg/5 mL, designed for both pediatric and adult patients who have difficulty swallowing tablets. These formulations contain eltrombopag olamine, a thrombopoietin receptor agonist that promotes platelet production by activating the c-Mpl receptor on bone marrow progenitor cells.

Major players in the eltrombopag drugs market are Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, Hetero Labs Limited, Dr. Reddy’s Laboratories Ltd, Alkem Laboratories Ltd, Granules India Ltd, Synthon BV, Metrochem API Pvt. Ltd, Taj Pharma India Ltd, Biophore India Pharmaceuticals Pvt. Ltd, Camber Pharmaceuticals Inc, Chunghwa Chemical Synthesis And Biotech Co. Ltd., Midas Pharma GmbH, Nuray Chemicals Private Limited, MSN Laboratories Private Limited, Aprazer Healthcare Private Limited, and Eskay Healthcare Private Limited.

North America was the largest region in the eltrombopag drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in eltrombopag drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the eltrombopag drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Eltrombopag drugs are medications designed to increase platelet counts in patients with conditions such as chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, and severe aplastic anemia. They function by stimulating the thrombopoietin receptor, thereby promoting platelet production in the bone marrow.

The primary forms of eltrombopag drugs are tablets and oral suspension. Eltrombopag tablets are oral medications used to elevate platelet counts in patients with thrombocytopenia by enhancing platelet production in the bone marrow. These drugs are applied in conditions including chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, severe aplastic anemia, and others. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and more, serving a range of end users including hospitals, clinics, homecare settings, and others.

The eltrombopag drugs market research report is one of a series of new reports that provides eltrombopag drugs market statistics, including eltrombopag drugs industry global market size, regional shares, competitors with an eltrombopag drugs market share, detailed eltrombopag drugs market segments, market trends and opportunities, and any further data you may need to thrive in the eltrombopag drugs industry. This eltrombopag drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The eltrombopag drugs market consists of sales of flavored suspension and tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.